irmsrct
What it found
The main measure showed a statistically significant benefit.
“The total attack number in the simvastatin group was significantly lower than placebo group (moderate effect size r = 0.29) (p = 0.01).”Read by software from the paper's abstract
effect size r 0.29
p = 0.01
Total participants: 85
Read by software from the paper's abstract
What was tested
Treatment tested
- Simvastatin
HMG-CoA reductase inhibitor
Placebo or sham
- placebo
What it measured
Main measures
attack number
1 year
Relapses
Who could take part
Relapsing MS · 15 to 60
Inclusion Criteria: 1. edss\<5 2. >=1 attack in last year Exclusion Criteria: 1. >2 attacks in study 2. drug complication
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.
Papers
Results
Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.Mult Scler · 2010
The total attack number in the simvastatin group was significantly lower than placebo group (moderate effect size r = 0.29) (p = 0.01).
Read by software from the paper's abstract
Loading reviews and guidelines…
Related trials
- Role of Simvastatin in Relapsing-Remitting Multiple Scler…
Phase 1 · Status unknown
No result found
- Simvastatin/Copaxone
Phase 3 · Withdrawn
Stopped early
- ARIANNA
Phase 2 · Completed
No result found
- SIMCOMBIN
Phase 4 · Completed
Result in a paper, not read yet
- A Safety Study of Combination Treatment With Avonex and Z…
Phase 3 · Status unknown
No result found
- SWABIMS
Phase 2 · Completed
Missed its main goal
History
Started
Apr 2005
Main results due
Mar 2008
Finished
Mar 2009
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error